GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment

What Was Tested

This randomized controlled trial paper looks at GIP (Gastric Inhibitory Polypeptide) in the context of osteoporosis and bone density.

The intestinal hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-2 (GLP-2) are key regulators of postprandial bone turnover in humans.

The researchers hypothesized that GIP and GLP-2 co-administration would provide stronger effect on bone turnover than administration of the hormones separately, and tested this using subcutaneous injections of GIP and GLP-2 alone or in combination in humans.

Who Took Part

According to the abstract, 10 men were involved.

PubMed indexes the participants as young adults and adults, both men and women.

How the Study Was Run

The design is described as randomized, single-blind and crossover.

Random assignment meant chance, not the researchers, decided who got GIP (Gastric Inhibitory Polypeptide) and who got the comparison, which limits bias.

Only one side, usually the men, was kept unaware of whether GIP (Gastric Inhibitory Polypeptide) was given.

In the crossover set-up each of the men took both GIP (Gastric Inhibitory Polypeptide) and the comparison in turn, acting as their own control.

What Was Measured

The intestinal hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-2 (GLP-2) are key regulators of postprandial bone turnover in humans.

The researchers hypothesized that GIP and GLP-2 co-administration would provide stronger effect on bone turnover than administration of the hormones separately, and tested this using subcutaneous injections of GIP and GLP-2 alone or in combination in humans.

The subject headings attached to it are Bone Remodeling, COS Cells, Chlorocebus aethiops, Gastric Inhibitory Polypeptide, Glucagon-Like Peptide 2, Glucagon-Like Peptide-2 Receptor and Mice, Inbred C57BL.

Author keywords: Bone turnover, Co-agonist, Dual-agonist, Glucagon-like peptide-2 (GLP-2), Glucose-dependent insulinotropic polypeptide (GIP) and Osteoporosis.

What This Means in Plain Language

The paper is a randomized, single-blind and crossover study of GIP (Gastric Inhibitory Polypeptide) in 10 men in people with osteoporosis and bone density.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2022 (Pharmacological research), a journal based in Netherlands.

More context: the GIP (Gastric Inhibitory Polypeptide) compound page, Osteoporosis and bone density research.